新辅助免疫联合放化疗治疗错配修复完整局部晚期直肠癌的系统综述与荟萃分析
该系统综述与荟萃分析纳入19项临床试验共1324例错配修复完整(pMMR)局部晚期直肠癌(LARC)患者,评估新辅助免疫检查点抑制剂(ICIs)联合放化疗(CRT)的疗效与毒性。结果显示联合方案显著提高总完全缓解(CR)率(42% vs 24%,P<0.001)和病理完全缓解(pCR)率(37% vs 24%,P=0.008),且毒性可控;化学免疫联合短程放疗较ICIs联合长程CRT进一步提高CR和pCR率。
要点
- 新辅助ICIs联合CRT较单纯CRT显著提高pMMR LARC的总CR率和pCR率。
- 化学免疫联合短程放疗的CR率(51%)和pCR率(48%)优于ICIs联合长程CRT。
- 联合方案≥3级治疗相关不良事件发生率为28%,与单纯CRT相似。
核心结论
- 新辅助免疫治疗联合放化疗是pMMR局部晚期直肠癌有前景的治疗策略,可提高完全缓解率且毒性可控。
- 化学免疫联合短程放疗表现出更优的疗效。
- 需进一步研究长期结局和最佳联合方案。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和Medline数据库。
- 纳入报告pCR或总CR率的I-III期临床试验,排除仅纳入错配修复缺陷(dMMR)LARC的研究。
- 共纳入19项试验,1324例患者,采用随机效应模型在试验水平和臂水平进行汇总分析。
主要发现
- 试验水平汇总:新辅助ICIs联合CRT的总CR率OR为1.72(95%CI 1.21-2.44),pCR率OR为1.68(95%CI 1.08-2.62)。
- 臂水平比较:联合方案较单纯CRT显著提高总CR率(42% vs 24%,P<0.001)和pCR率(37% vs 24%,P=0.008)。
- 化学免疫联合短程放疗较ICIs联合长程CRT显著提高总CR率(51% vs 36%)和pCR率(48% vs 30%),均P<0.001。
- 1-2级和≥3级治疗相关不良事件汇总发生率分别为63%和28%,与单纯CRT相似。
关键数值与推荐
- 主要结局为pCR率和总CR率(pCR+临床CR)。
- 试验水平总CR率OR 1.72(95%CI 1.21-2.44),pCR率OR 1.68(95%CI 1.08-2.62)。
- 臂水平联合方案总CR率42% vs 24%(P<0.001),pCR率37% vs 24%(P=0.008)。
- 化学免疫联合短程放疗总CR率51% vs 36%,pCR率48% vs 30%(均P<0.001)。
- 1-2级治疗相关不良事件发生率63%,≥3级28%。
临床怎么用
- 对于pMMR局部晚期直肠癌,可考虑新辅助ICIs联合CRT以提高完全缓解率。
- 化学免疫联合短程放疗可作为优先考虑的联合模式之一。
- 治疗决策时需结合毒性谱(≥3级不良事件28%)进行个体化评估。
局限性
- 原文未报告所纳入试验的具体异质性评估结果。
- 原文未报告长期生存结局(如无病生存期、总生存期)的汇总数据。
- 原文未报告最佳联合方案的具体推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the efficacy and toxicity of combining neoadjuvant immune checkpoint inhibitors (ICIs) with chemoradiotherapy (CRT) for patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC). METHODS: PubMed, Embase, Cochrane Library, and Medline databases were searched. Phase I-III clinical trials reporting pathologic complete response (pCR) or overall CR (pCR + clinical CR) rates for neoadjuvant ICIs plus CRT in pMMR LARC were included. Studies that only enrolled patients with mismatch repair-deficient LARC were excluded. Data were analyzed at trial and arm levels and pooled using random-effects models. Primary outcomes were pCR and overall CR rates. Toxicity occurrence was also measured. RESULTS: In total, 19 trials (n = 1324) were included. At trial level, pooled odds ratios (95 % CIs) of overall CR and pCR rates for neoadjuvant ICIs plus CRT were 1.72 (1.21-2.44) and 1.68 (1.08-2.62), respectively. At arm level, compared with CRT, neoadjuvant ICIs plus CRT significantly improved overall CR (42 % vs 24 %, P < 0.001) and pCR rates (37 % vs 24 %, P = 0.008). Compared with ICIs plus long-course CRT, chemoimmunotherapy plus short-course radiotherapy significantly increased overall CR (51 % vs 36 %) and pCR (48 % vs 30 %) rates (both P < 0.001). Pooled incidence of grade 1-2 and ≥ 3 treatment-related adverse events was 63 % and 28 %, respectively-similar to CRT alone. CONCLUSION: Neoadjuvant immunotherapy plus CRT is a promising treatment strategy for pMMR LARC, with improved CR rates and manageable toxicity. Chemoimmunotherapy plus short-course radiotherapy exhibits superior efficacy. Further investigation on long-term outcomes and optimal combined regimens is warranted.
引用
- Wang Y, Liu Y, Guan X, et al. Neoadjuvant immunotherapy and chemoradiotherapy for mismatch repair proficient locally advanced rectal cancer: A systematic review and meta-analysis. Radiother Oncol. 2025. PMID: 40759282. doi:10.1016/j.radonc.2025.111073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。